The biospecimens collection will be a valuable resource for continued translational studies.Ģ019 Update: An early analysis of the first 381 patients out of a planned 1,000 was presented at ESMO Breast Cancer Congress in May 2019. These efforts will lead to more efficient clinical trials and better management of metastatic breast cancer. Tumor tissue, blood, serum, and plasma samples are being analyzed to identify genes and gene-outputs driving metastasis, as well as blood-based biomarkers that can be used to non-invasively determine tumor progression and treatment response. The study has recruited more than 1,100 women and men with metastatic breast cancer from 60 hospitals in 11 EU countries. The objective of the AURORA programs is to conduct precise, multi-level molecular analyses of breast cancer metastases and the primary tumors they come from to better understand the evolution of metastasis and the mechanisms of drug resistance that allow tumors to grow and spread.ĪURORA EU benefits from the collaborative infrastructure of BIG-the world’s largest network of international academic research groups comprised of 55 groups across 70 countries and six continents.
Antonio Wolff and Ian Krop through the Translational Breast Cancer Research Consortium (TBCRC) based at Johns Hopkins University. Nancy Davidson with clinical aspects being administered by Drs. The flagship programs of the Founder’s Fund are: AURORA EU, based in Brussels and conducted under the oversight of Dr. Martine Piccart through the Breast International Group (BIG) and AURORA US, coordinated by Dr. BCRF has dedicated $41.5 million to this important initiative to date. These discoveries are paving the way to being able to identify aggressive breast cancers before they become lethal and find new targets for treatment and prevention. These efforts are yielding new insights into the molecular changes that occur as breast cancer evolves from a localized disease in the breast to one that has spread to one or more vital organs. BCRF investigators from around the world are using the most advanced tools of molecular analysis-some developed with BCRF support-to dissect the molecular basis of metastasis in real people in real time. No area in cancer medicine is more pressing and no opportunity more significant than understanding and stopping metastasis. The Founder’s Fund, an international, multi-year collaboration, is the cornerstone of BCRF’s overall investment in metastatic breast cancer, which represents, on average, 40 percent of our annual research grant portfolio.
Lauder Founder’s Fund for Metastatic Breast Cancer Research (The Founder’s Fund), was fueled by an outpouring of support honoring the memory and immutable determination of BCRF’s founder, Evelyn H. This initiative, now known as the Evelyn H. Clifford Hudis, BCRF established a dedicated initiative to address the persistent challenges of breast cancer metastasis. Larry Norton and former Scientific Advisory Board Chair Dr. In 2013, under the direction of our Founding Scientific Director Dr. alone are living with metastatic breast cancer-and that number is projected to rise. As of 2020, an estimated 168,000 individuals in the U.S. While there has been significant progress in early detection and treatment for primary breast cancer, advances in treatment and prevention of metastasis are still needed. For 25 to 30 percent of these women, their cancer will spread, or metastasize. will develop breast cancer in her lifetime.
0 kommentar(er)
